Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety
of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus
Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary
Tract Cancers